World / US offers $486 mn to AstraZeneca to secure 1L COVID-19 antibody doses

US government has awarded $486 million to pharmaceutical firm AstraZeneca Plc to develop and secure up to 1,00,000 doses of COVID-19 antibody treatment, as per a Reuters report. The agreement under President Donald Trump administration's Operation Warp Speed is aimed at developing monoclonal antibody cocktail, especially for those at higher risk, US Department of Health and Human Services said.

Vikrant Shekhawat : Oct 10, 2020, 04:31 PM
Washington: U.S. Department of Health and Human Services on Friday signed an agreement with AstraZeneca Plc for development and supply of the company’s COVID-19 antibody treatment, a cocktail of two monoclonal antibodies - similar class of drugs that was administered to President Donald Trump.

The agency will provide nearly $486 million to AstraZeneca for two Phase 3 clinical trials as well as a large-scale manufacturing demonstration project and supply of AZD7442 doses in the United States.